PsychedelicNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) DehydraTech™ Shines in Vegas Lights

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) attracted a lot of attention in Las Vegas at this year’s Marijuana Business Conference & Expo due to increased awareness about potential health benefits of cannabinoids and an increased demand for improved CBD-based edibles. A recent article highlights keen interest in Lexaria’s patented DehydraTECH™ delivery technology, stating, “Lexaria’s proprietary technology has been awarded patents in the U.S. and Australia, and it has patents pending in more than 40 other countries. Furthermore, it is the only company in the world to date that has a patent allowed for the oral delivery of all non-psychoactive cannabinoids, including CBD, as well as for the delivery of THC and other psychoactive cannabinoids. This delivery technology masks the taste of edibles, eliminating the need for unhealthy sugars and sweeteners used in many products to mask bitter flavors. It also increases bio-absorption of cannabinoids and other active compounds by up to 10 times and reduces the time of onset of effects, which were previously typically 60 to 120 minutes, to between 15 and 20 minutes. These capabilities are in marked contrast to other technologies through which active compounds are bad tasting upon oral intake, broken down by the liver, largely destroyed by stomach acid and unable to cross the intestinal wall to any significant degree.”

To view the full article, visit http://cnw.fm/0PFHn

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and was granted its first patents in the USA and in Australia related to edible forms of cannabinoids. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaEnergy.com.

More from PsychedelicNewsBreaks

• PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference
• PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Re-files ANDA for Preservative-Free IV Ketamine KETAFREE(TM)
• PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives FDA Approval of Suitability Petition for Preservative-Free Ketamine Product

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) PsychedelicNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. PNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled visibility, recognition and brand awareness. PNW is where news, content and information converge.

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/disclaimer/

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com